Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00636168
Registration number
NCT00636168
Ethics application status
Date submitted
7/03/2008
Date registered
14/03/2008
Date last updated
17/12/2019
Titles & IDs
Public title
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Query!
Scientific title
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Query!
Secondary ID [1]
0
0
EORTC 18071
Query!
Secondary ID [2]
0
0
CA184-029
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
High Risk Stage III Melanoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Malignant melanoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - ipilimumab
Treatment: Drugs - Placebo
Active Comparator: A -
Placebo Comparator: B -
Treatment: Drugs: ipilimumab
IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Treatment: Drugs: Placebo
IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Recurrence Free Survival (RFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population
Query!
Assessment method [1]
0
0
Recurrence free survival (RFS) was programmatically determined based on the disease recurrence data provided by the IRC and was defined as the time between the date of randomization and the date of first recurrence or death (whatever the cause), whichever occurred first. A participant who died without reported recurrence was considered to have recurrence on the date of death. For those participants who remained alive and recurrence-free, RFS was censored on the date of last evaluable post-randomization tumor assessment. For those who remained alive and had no recorded post-randomization tumor assessment, RFS was censored on the day of randomization. Participants with disease at baseline were considered to have an event on the day of randomization. Computerized tomography (CT) and magnetic resonance imaging (MRI) were mandatory to establish recurrence. The primary analysis was event-driven and planned when at least 512 RFS events assessed per IRC were collected.
Query!
Timepoint [1]
0
0
Date of randomization to first date of recurrence or death or last available disease assessment with RFS data up to 5 years. Median follow-up was 2.7 years.
Query!
Primary outcome [2]
0
0
Number of Participants With Recurrence or Death as Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population
Query!
Assessment method [2]
0
0
Recurrence was defined as appearance of one or more new melanoma lesions: local, regional or distant metastasis. Computerized tomography (CT) and magnetic resonance imaging (MRI) were mandatory to establish recurrence. A participant who died without reported recurrence was considered to have recurred on the date of death. Disease was assessed at randomization and every 12 weeks (±2 weeks) for 3 years, then every 24 weeks until documented distant progression.
Query!
Timepoint [2]
0
0
Date of randomization to first date of recurrence or death or last available disease assessment with RFS data upto 5 years. Median follow-up was 2.7 years.
Query!
Primary outcome [3]
0
0
Recurrence-Free Survival (RFS) Rates Per IRC at 1 Year, 2 Years, and 3 Years in the ITT Population
Query!
Assessment method [3]
0
0
Yearly recurrence-free survival rates, eg. at 1 year, defined as the probability that a participant was recurrence-free at 1 year following randomization, were estimated for each treatment group using the Kaplan-Meier product-limit method, along with their corresponding log-log transformed 95% confidence intervals. RFS was defined as the time between the date of randomization and the date of first recurrence or death (whatever the cause), whichever occurred first. A participant who died without reported recurrence was considered to have recurrence on the date of death. For those who remained alive and recurrence-free, RFS was censored on the date of last evaluable post-randomization tumor assessment. For those who remained alive and had no recorded post-randomization tumor assessment, RFS was censored on the day of randomization. Participants with disease at baseline were considered to have an event on the day of randomization. CT and MRI were mandatory to establish recurrence.
Query!
Timepoint [3]
0
0
At years 1, 2, and 3
Query!
Secondary outcome [1]
0
0
Distant Metastasis-Free Survival (DMFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population
Query!
Assessment method [1]
0
0
Distant Metastasis-Free Survival (DMFS) was programmatically determined based on the first date of distant metastasis provided by the IRC and was defined as the time between the date of randomization and the date of first distant metastasis or death (whatever the cause), whichever occurred first. A participant who died without reported disease distant metastasis was considered to have distant metastasis on the date of death. For those who remained alive and metastasis-free, DMFS was censored on the date of last evaluable post-randomization tumor assessment. For those who remained alive and had no recorded post-randomization tumor assessment, DMFS was censored on the day of randomization. Participants with disease at baseline were considered to have an event on the day of randomization. Disease was assessed at baseline (randomization) and every 12 weeks (±2 weeks) for 3 years, then every 24 weeks until documented distant progression.
Query!
Timepoint [1]
0
0
From June 2008 to January 2016 (approximately 90 months)
Query!
Secondary outcome [2]
0
0
Number of Participants With Distant Metastasis-Free Survival (DMFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population
Query!
Assessment method [2]
0
0
DMFS was programmatically determined based on the first date of distant metastasis provided by the IRC and was defined as the time between the date of randomization and the date of first distant metastasis or death (whatever the cause), whichever occurred first. A participant who died without reported disease distant metastasis was considered to have distant metastasis on the date of death. For those who remained alive and metastasis-free, DMFS was censored on the date of last evaluable post-randomization tumor assessment. For those who remained alive and had no recorded post-randomization tumor assessment, DMFS was censored on the day of randomization. Participants with disease at baseline were considered to have an event on the day of randomization. Disease was assessed at baseline (randomization) and every 12 weeks (2 weeks) for 3 years, then every 24 weeks until documented distant progression.
Query!
Timepoint [2]
0
0
From June 2008 to January 2016 (approximately 90 months)
Query!
Secondary outcome [3]
0
0
Distant Metastasis-Free Survival (DMFS) Rates Per IRC at 1 Year, 2 Years, 3 Years, 4 Years and 5 Years in the ITT Population
Query!
Assessment method [3]
0
0
Yearly distant metastasis-free survival rates, e.g. at 1 year, defined as the probability that a participant was alive at 1 year following randomization, were estimated via the Kaplan-Meier method. Distant Metastasis-Free Survival (DMFS) was programmatically determined based on the first date of distant metastasis provided by the IRC and was defined as the time between the date of randomization and the date of first distant metastasis or death (whatever the cause), whichever occurred first. A participant who died without reported disease distant metastasis was considered to have distant metastasis on the date of death. For those who remained alive and metastasis-free, DMFS was censored on the date of last evaluable post-randomization tumor assessment. For those who remained alive and had no recorded post-randomization tumor assessment. Participants with disease at baseline were considered to have an event on the day of randomization.
Query!
Timepoint [3]
0
0
At years 1, 2, 3, 4 and 5
Query!
Secondary outcome [4]
0
0
Overall Survival in the Intent to Treat (ITT) Population
Query!
Assessment method [4]
0
0
OS was defined as the time from the date of randomization to the date of death. For those participants who had not died, OS was censored at the recorded last non-missing date of contact for which the participant was known to be alive.
Query!
Timepoint [4]
0
0
From June 2008 to January 2016 (approximately 90 months)
Query!
Secondary outcome [5]
0
0
Rate of Overall Survival (OS)
Query!
Assessment method [5]
0
0
OS was defined as the time from the date of randomization to the date of death. For those participants who had not died, OS was censored at the recorded last non-missing date of contact for which the participant was known to be alive.Yearly survival rates, e.g. at 3 years, defined as the probability that a participant was alive at 3 years following randomization, were estimated via the Kaplan-Meier method
Query!
Timepoint [5]
0
0
From date of randomization to date of death, assessed up to 9 years
Query!
Secondary outcome [6]
0
0
Number of Participants With On-Study Adverse Events (AEs) Leading to Discontinuation of Treatment, Serious AEs (SAEs), Drug-Related SAEs, Immune-related AEs (irAEs), Immune-mediated Adverse Reactions (imARs), Deaths in Treated Population
Query!
Assessment method [6]
0
0
AEs: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1. irAEs=unknown etiology consistent with an immune phenomenon, considered as causally related to drug. imARs=based on investigator's assessment of immune-mediated etiology [excluding novel maintenance events (ie, patients with imARs occurring for the first time during maintenance)]. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Drug-related (D-R)=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling, Gr 5=Death.
Query!
Timepoint [6]
0
0
Day 1 up to 70 days after last dose; up to 5 years
Query!
Secondary outcome [7]
0
0
Number of Participants With Serious Adverse Events (SAEs), Non-serious AEs (NSAEs) and Number of Deaths: Overall Study
Query!
Assessment method [7]
0
0
AEs: Medical Dictionary for Regulatory Activities (MedDRA) version 16.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.
Query!
Timepoint [7]
0
0
SAEs and NSAEs: Day 1 up to 70 days after last dose(safety window). Deaths: All deaths regardless of 70 day safety window.Up to 10 years
Query!
Secondary outcome [8]
0
0
Exposure Adjusted Incidence Rate of Adverse Events Including Multiple Occurrences of Unique Events
Query!
Assessment method [8]
0
0
P-Y = person-years of exposure. Incidence rate per 100 person-years of exposure (IR/100 P-Y) was calculated as event count * 100 /person-years of exposure. MedDRA Version: 19. Duplicate AEs have been eliminated and overlapping and contiguous occurrences of the same event have been collapsed.
Query!
Timepoint [8]
0
0
Day 1 up to 70 days after last dose; up to 5 years
Query!
Secondary outcome [9]
0
0
Mean Change From Baseline in Global Health Status Scores at Each Assessment Timepoint
Query!
Assessment method [9]
0
0
Global health status was measured using European Organization for Research and Treatment of Cancer (EORTC) Quality Life Questionnaire (QLQ) C-30. This health related quality of life (HRQoL) questionnaire was comprised of 15 questions on functional scales, 13 questions on symptom scales and 2 on global health status scale. Global Health Status used a 7 point Likert-type scale of 1 (Very poor) to 7 (Excellent). All scales linearly transformed to 0-100 scales. Higher scores for Global Health Status indicate better HRQoL. An increase from baseline indicates improvement in HRQoL compared to baseline. HRQoL was administered within 1 week prior to first dose (baseline) and on Days 22, 43, 64 (+/- 3 days), Week 24 and every 12 weeks up to 2 years, independent of disease progression.
Query!
Timepoint [9]
0
0
Baseline up to 2 years from randomization
Query!
Eligibility
Key inclusion criteria
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.
- Age = 18 years
- Complete and adequate resection of Stage III melanoma with histologically confirmed
melanoma metastatic to lymph node
- Disease-free
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
- Randomization within 12 weeks of surgery
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Prior therapy for melanoma except surgery
- Auto-immune disease
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
30/06/2008
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/11/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1211
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Local Institution - Waratah
Query!
Recruitment hospital [2]
0
0
Local Institution - Westmead
Query!
Recruitment hospital [3]
0
0
Local Institution - Greenslopes
Query!
Recruitment hospital [4]
0
0
Local Institution - Woolloongabba
Query!
Recruitment hospital [5]
0
0
Local Institution - Box Hill
Query!
Recruitment hospital [6]
0
0
Local Institution - Malvern
Query!
Recruitment hospital [7]
0
0
Local Institution - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [2]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [3]
0
0
4120 - Greenslopes
Query!
Recruitment postcode(s) [4]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [5]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [6]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [7]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Connecticut
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Missouri
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Nevada
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New Jersey
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Mexico
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
North Carolina
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Pennsylvania
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Tennessee
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Texas
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Utah
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Washington
Query!
Country [17]
0
0
Austria
Query!
State/province [17]
0
0
Graz
Query!
Country [18]
0
0
Austria
Query!
State/province [18]
0
0
Wien
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Gent
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Leuven
Query!
Country [21]
0
0
Canada
Query!
State/province [21]
0
0
Alberta
Query!
Country [22]
0
0
Canada
Query!
State/province [22]
0
0
Quebec
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Praha 2
Query!
Country [24]
0
0
Denmark
Query!
State/province [24]
0
0
Aarhus C
Query!
Country [25]
0
0
Denmark
Query!
State/province [25]
0
0
Herlev
Query!
Country [26]
0
0
Denmark
Query!
State/province [26]
0
0
Odense C
Query!
Country [27]
0
0
Finland
Query!
State/province [27]
0
0
Helsinki
Query!
Country [28]
0
0
Finland
Query!
State/province [28]
0
0
Turku
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Cedex
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Boulogne-billancourt
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Marseille Cedex 5
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Paris
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Pierre Benite
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Vandoeuvre Les Nancy
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Villejuif
Query!
Country [36]
0
0
Germany
Query!
State/province [36]
0
0
Berlin
Query!
Country [37]
0
0
Germany
Query!
State/province [37]
0
0
Essen
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Gottingen
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Heidelberg
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Kiel
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Koln
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Luebeck
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Mannheim
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Tubingen
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Wurzburg
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Genova
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Milano
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Napoli
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Padova
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Roma
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Siena
Query!
Country [52]
0
0
Netherlands
Query!
State/province [52]
0
0
Amsterdam
Query!
Country [53]
0
0
Netherlands
Query!
State/province [53]
0
0
Leiden
Query!
Country [54]
0
0
Netherlands
Query!
State/province [54]
0
0
Nijmegen
Query!
Country [55]
0
0
Netherlands
Query!
State/province [55]
0
0
Rotterdam
Query!
Country [56]
0
0
Norway
Query!
State/province [56]
0
0
Oslo
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Poznan
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Warszawa
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
Stavropol Region
Query!
Country [60]
0
0
Russian Federation
Query!
State/province [60]
0
0
Ivanovo
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Izhevsk
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Krasnodar
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Krasnoyarsk
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Lipetsk
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Moscow
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Petrozavodsk
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Saratov
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
St Petersburg
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
St. Petersburg
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Tomsk
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
Ufa
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Barcelona
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Madrid
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Zaragoza
Query!
Country [75]
0
0
Sweden
Query!
State/province [75]
0
0
Stockholm
Query!
Country [76]
0
0
Switzerland
Query!
State/province [76]
0
0
Zurich
Query!
Country [77]
0
0
United Kingdom
Query!
State/province [77]
0
0
Essex
Query!
Country [78]
0
0
United Kingdom
Query!
State/province [78]
0
0
Greater London
Query!
Country [79]
0
0
United Kingdom
Query!
State/province [79]
0
0
Hampshire
Query!
Country [80]
0
0
United Kingdom
Query!
State/province [80]
0
0
Nottinghamshire
Query!
Country [81]
0
0
United Kingdom
Query!
State/province [81]
0
0
Yorkshire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Bristol-Myers Squibb
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of the study is to determine if ipilimumab is effective in preventing or delaying
recurrence and prolongs survival after complete resection of high risk stage III melanoma
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00636168
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Bristol-Myers Squibb
Query!
Address
0
0
Bristol-Myers Squibb
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00636168
Download to PDF